Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems

Shao, Huimin; Varamini, Pegah

doi:10.3390/cells11030388

Cited by 21 publications

(13 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment options for BC bone metastasis is hindered by the complex bone microstructure and a lack of an EPR effect due to low blood flow ( 56 ). Hence, non-targeted liposomes/LNP may have limited accumulation in the bones due to their size and low penetrability of the bone ( 71 ). Active targeting strategies could be taken into consideration when using liposomes/LNP to treat bone metastasis, including targeting both the tumor microenvironment and cancer cells simultaneously.…”

Section: Metastatic Breast Cancer Treatments Via L...mentioning

confidence: 99%

Advances in lipid-based nanocarriers for breast cancer metastasis treatment

Joun

Nixdorf²,

Deng³

2022

Front. Med. Technol.

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cancer affecting women worldwide, with over 2 million women diagnosed every year, and close to 8 million women currently alive following a diagnosis of BC in the last 5-years. The side effects such as chemodrug toxicity to healthy tissues and drug resistance severely affect the quality of life of BC patients. To overcome these limitations, many efforts have been made to develop nanomaterial-based drug delivery systems. Among these nanocarriers, lipid-based delivery platforms represented one of the most successful candidates for cancer therapy, improving the safety profile and therapeutic efficacy of encapsulated drugs. In this review we will mainly discuss and summarize the recent advances in such delivery systems for BC metastasis treatment, with a particular focus on targeting the common metastatic sites in bone, brain and lung. We will also provide our perspectives on lipid-based nanocarrier development for future clinical translation.

show abstract

Section: Metastatic Breast Cancer Treatments Via L...mentioning

confidence: 99%

Advances in lipid-based nanocarriers for breast cancer metastasis treatment

Joun

Nixdorf²,

Deng³

2022

Front. Med. Technol.

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that about 0.16 million patients were affected by BC in the United States in 2017 ( Torre et al, 2016 ; Li et al, 2020a ). Since 2020, there have been 2.3 million new cases of BC worldwide every year, and the total number of BC patients is predicted to increase by 50% by 2040 ( Dias et al, 2021 ; Shao and Varamini, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Recent advances in photothermal therapy-based multifunctional nanoplatforms for breast cancer

Sun

Zhao

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common cancers in women worldwide; however, the successful treatment of BC, especially triple-negative breast cancer (TNBC), remains a significant clinical challenge. Recently, photothermal therapy (PTT), which involves the generation of heat under irradiation to achieve photothermal ablation of BC with minimal invasiveness and outstanding spatial–temporal selectivity, has been demonstrated as a novel therapy that can overcome the drawbacks of chemotherapy or surgery. Significantly, when combining PTT with chemotherapy and/or photodynamic therapy, an enhanced synergistic therapeutic effect can be achieved in both primary and metastatic BC tumors. Thus, this review discusses the recent developments in nanotechnology-based photothermal therapy for the treatment of BC and its metastasis to provide potential strategies for future BC treatment.

show abstract

“…According to the Report of the American Cancer Society, BC is second only to lung cancer in the number of cancer-related deaths among women. In recent years, the incidence of BC has been increasing at an annual rate of approximately 0.3%, with 2.3 million new cases worldwide in 2020 and a significant increase in mortality from 1990 to 2015 (3,4). According to Surveillance, Epidemiology and End Results (SEER) data, the 5-year survival rate of patients with stage IIIA and stage IIIB BC was 52% and 48%, respectively, and the median survival of patients with stage III BC was 4.9 years (2,(5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignant tumor in women. There are different risk characteristics and treatment strategies for different subtypes of BC. The tumor microenvironment (TME) is of great significance for understanding the occurrence, development, and metastasis of tumors. The TME plays an important role in all stages of BC metastasis, immune monitoring, immune response avoidance, and drug resistance, and also plays an important role in the diagnosis, prevention, and prognosis of BC. Smart nanosystems have broad development prospect in the regulation of the BC drug delivery based on the response of the TME. In particular, TME-responsive nanoparticles cleverly utilize the abnormal features of BC tissues and cells to achieve targeted transport, stable release, and improved efficacy. We here present a review of the mechanisms underlying the response of the TME to BC to provide potential nanostrategies for future BC treatment.

show abstract

Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems

Cited by 21 publications

References 109 publications

Advances in lipid-based nanocarriers for breast cancer metastasis treatment

Advances in lipid-based nanocarriers for breast cancer metastasis treatment

Recent advances in photothermal therapy-based multifunctional nanoplatforms for breast cancer

Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment

Contact Info

Product

Resources

About